Top News

We’re not joining the sellers of Eli Lilly after its earnings results

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 

George Frey | Bloomberg | Getty Images

Eli Lilly’s fourth-quarter results and 2024 sales guidance topped Wall Street expectations Tuesday, strengthening our investment case in the world’s most valuable drugmaker and prompting us to boost our price target on the stock.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button